Tiagabine Treatment is Associated with Neurochemical, Immune and Behavioural Alterations in the Olfactory Bulbectomized Rat Model of Depression

 

 Buy Article Permissions and Reprints

Abstract

Introduction: Affective disorders are often associated with immune and neuroendocrine disturbances. However, little information on the modulatory effects of antiepileptics on endocrine and immune functions is available. Some novel antiepileptics, including tiagabine, are considered as potential antidepressants.

Methods: We investigated the influence of tiagabine on stress hormone release, cellular immune function and behaviour in rats following olfactory bulbectomy (OB), a well-recognized animal model of depression.

Results: Hyperlocomotion in the open field, typical for the OB rodents, was attenuated by repeated treatment with tiagabine (12 mg/kg/day) in a similar fashion to standard antidepressants. OB led to significantly decreased lymphocyte and increased neutrophil counts, and suppressed leukocyte phagocytosis. The OB-induced changes in leukocyte differential counts were not found in the tiagabine-treated group. The OB-induced reduction in plasma noradrenaline levels was normalized following tiagabine treatment.

Discussion: The present data bring further evidence on the antidepressant-like action of tiagabine and encourage further research on its use in the treatment of affective disorders. The obser-ved changes in immune and endocrine functions may contribute to its mood stabilizing effect.

References

• 1 Barden N. Implication of the hypothalamic-pituitary-adrenal axis in the physiopathology of depression.  J Psychiatry Neurosci. 2004;  29 185-193
  PubMedGoogle Scholar
• 2 Bersudsky Y. Phenytoin: an anti-bipolar anticonvulsant?.  Int J Neuropsychopharmacol. 2006;  9 479-484
  CrossrefPubMedGoogle Scholar
• 3 Carney R-M, Freedland K-E, Veith R-C. Depression, the autonomic nervous system, and coronary heart disease.  Psychosom Med. 2005;  67 ((Suppl 1)) S29-S33
  CrossrefPubMedGoogle Scholar
• 4 Carta M-G, Hardoy M-C, Grunze H, Carpiniello B. The use of tiagabine in affective disorders.  Pharmacopsychiatry. 2002;  35 33-34
  Article in Thieme ConnectPubMedGoogle Scholar
• 5 Cryan J-F, Mombereau C. In search of a depressed mouse: utility of models for studying depression-related behaviour in genetically modified mice.  Mol Psychiatry. 2004;  9 326-357
  CrossrefPubMedGoogle Scholar
• 6 de Boer S-F, Slangen J-L, Van der Gugten J. Effects of chlordiazepoxide and buspirone on plasma catecholamine and corticosterone levels in rats under basal and stress conditions.  Endocrinol Exp. 1990;  24 229-239
  PubMedGoogle Scholar
• 7 Delbende C, Tranchand B-D, Tarozzo G, Grino M, Oliver C, Mocaer E. et al . Effect of chronic treatment with the antidepressant tianeptine on the hypothalamo-pituitary-adrenal axis.  Eur J Pharmacol. 1994;  251 245-251
  CrossrefPubMedGoogle Scholar
• 8 Fenn H-H, Sommer B-R, Ketter T-A, Alldredge B. Safety and tolerability of mood-stabilising anticonvulsants in the elderly.  Expert Opin Drug Saf. 2006;  5 401-416
  CrossrefPubMedGoogle Scholar
• 9 Franklin M, Hafizi S, Reed A, Hockney R, Murck H. Effect of sub-chronic treatment with Jarsin (extract of St John's wort, Hypericum perforatum) at two dose levels on evening salivary melatonin and cortisol concentrations in healthy male volunteers.  Pharmacopsychiatry. 2006;  39 13-15
  Article in Thieme ConnectPubMedGoogle Scholar
• 10 Gajwani P, Forsthoff A, Muzina D, Amann B, Gao K, Elhaj O. et al . Antiepileptic drugs in mood-disordered patients.  Epilepsia. 2005;  46 ((Suppl 4)) 38-44
  PubMedGoogle Scholar
• 11 Gilmor M-L, Skelton K-H, Nemeroff C-B, Owens M-J. The effects of chronic treatment with the mood stabilizers valproic acid and lithium on corticotropin-releasing factor neuronal systems.  J Pharmacol Exp Ther. 2003;  305 434-439
  CrossrefPubMedGoogle Scholar
• 12 Invitti C, Danesi L, Dubini A, Cavagnini F. Neuroendocrine effects of chronic administration of sodium valproate in epileptic patients.  Acta Endocrinol (Copenh). 1988;  118 381-388
  PubMedGoogle Scholar
• 13 Jezova D, Guillaume V, Jurankova E, Carayon P, Oliver C. Studies on the physiological role of ANF in ACTH regulation.  Endocr Regul. 1994;  28 163-169
  PubMedGoogle Scholar
• 14 Jezova D, Makatsori A, Duncko R, Moncek F, Jakubek M. High trait anxiety in healthy subjects is associated with low neuroendocrine activity during psychosocial stress. Prog. Neuropsychopharmacol.  Biol Psychiatry. 2004;  28 1331-1336
  PubMedGoogle Scholar
• 15 Jezova D. Control of ACTH secretion by excitatory amino acids: functional significance and clinical implications.  Endocrine. 2005;  28 287-294
  CrossrefPubMedGoogle Scholar
• 16 Kelly J-P, Wrynn A-S, Leonard B-E. The olfactory bulbectomized rat as a model of depression: an update.  Pharmacol Ther. 1997;  74 299-316
  CrossrefPubMedGoogle Scholar
• 17 Knyszynski A, Fischer H. Circadian fluctuations in the activity of phagocytic cells in blood, spleen, and peritoneal cavity of mice as measured by zymosan-induced chemiluminescence.  J Immunol. 1981;  127 2508-2511
  PubMedGoogle Scholar
• 18 Leonard B-E. The immune system, depression and the action of antidepressants.  Prog Neuropsychopharmacol Biol Psychiatry. 2001;  25 767-780
  CrossrefPubMedGoogle Scholar
• 19 Leonard B-E, Tuite M. Anatomical, physiological, and behavioral aspects of olfactory bulbectomy in the rat.  Int Rev Neurobiol. 1981;  22 251-286
  PubMedGoogle Scholar
• 20 Lilius E-M, Mertsola J, Leivo P, Kuronen T, Ruuskanen O. A rapid and simple method for evaluation of serum opsonic capacity against Bordetella pertussis by chemiluminescence.  Dev Biol Stand. 1985;  61 373-377
  PubMedGoogle Scholar
• 21 Lloyd K-G, Morselli P-L, Depoortere H, Fournier V, Zivkovic B, Scatton B. et al . The potential use of GABA agonists in psychiatric disorders: evidence from studies with progabide in animal models and clinical trials.  Pharmacol Biochem Behav. 1983;  18 957-966
  CrossrefPubMedGoogle Scholar
• 22 Makatsori A, Duncko R, Moncek F, Loder I, Katina S, Jezova D. Modulation of neuroendocrine response and non-verbal behavior during psychosocial stress in healthy volunteers by the glutamate release-inhibiting drug lamotrigine.  Neuroendocrinology. 2004;  79 34-42
  CrossrefPubMedGoogle Scholar
• 23 Marcilhac A, Faudon M, Anglade G, Hery F, Siaud P. An investigation of serotonergic involvement in the regulation of ACTH and corticosterone in the olfactory bulbectomized rat.  Pharmacol Biochem Behav. 1999;  63 599-605
  CrossrefPubMedGoogle Scholar
• 24 Moffitt J-A, Grippo A-J, Holmes P-V, Johnson A-K. Olfactory bulbectomy attenuates cardiovascular sympathoexcitatory reflexes in rats.  Am J Physiol Heart Circ Physiol. 2002;  283 H2575-H2583
  PubMedGoogle Scholar
• 25 Molina P-E. Neurobiology of the stress response: contribution of the sympathetic nervous system to the neuroimmune axis in traumatic injury.  Shock. 2005;  24 3-10
  CrossrefPubMedGoogle Scholar
• 26 Montilla P, Varo A, Munoz M-C. Effect of olfactory bulbectomy on plasma levels of glucose, lipids and corticosterone in the rat.  Rev Esp Fisiol. 1984;  40 47-51
  PubMedGoogle Scholar
• 27 Peuler J-D, Johnson G-A. Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine and dopamine.  Life Sci. 1977;  21 625-636
  CrossrefPubMedGoogle Scholar
• 28 Pistovcakova J, Makatsori A, Sulcova A, Jezova D. Felbamate reduces hormone release and locomotor hypoactivity induced by repeated stress of social defeat in mice.  Eur Neuropsychopharmacol. 2005;  15 153-158
  CrossrefPubMedGoogle Scholar
• 29 Reul J-M, Stec I, Soder M, Holsboer F. Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system.  Endocrinology. 1993;  133 312-320
  CrossrefPubMedGoogle Scholar
• 30 Roche M, Harkin A, Kelly J-P. Chronic fluoxetine treatment attenuates stressor-induced changes in temperature, heart rate, and neuronal activation in the olfactory bulbectomized rat.  Neuropsychopharmacology. 2007;  32 1312-1320
  CrossrefPubMedGoogle Scholar
• 31 Rosenthal M. Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control.  J Clin Psychiatry. 2003;  64 1245-1249
  CrossrefPubMedGoogle Scholar
• 32 Rozanski A, Blumenthal J-A, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy.  Circulation. 1999;  99 2192-2217
  CrossrefPubMedGoogle Scholar
• 33 Schmitt U, Luddens H, Hiemke C. Anxiolytic-like effects of acute and chronic GABA transporter inhibition in rats.  J Neural Transm. 2002;  109 871-880
  CrossrefPubMedGoogle Scholar
• 34 Schousboe A, Sarup A, Larsson O-M, White H-S. GABA transporters as drug targets for modulation of GABAergic activity.  Biochem Pharmacol. 2004;  68 1557-1563
  CrossrefPubMedGoogle Scholar
• 35 Slotkin T-A, Cousins M-M, Tate C-A, Seidler F-J. Serotonergic cell signaling in an animal model of aging and depression: olfactory bulbectomy elicits different adaptations in brain regions of young adult vs aging rats.  Neuropsychopharmacology. 2005;  30 52-57
  PubMedGoogle Scholar
• 36 Song C, Leonard B-E. The olfactory bulbectomised rat as a model of depression.  Neurosci Biobehav Rev. 2005;  29 627-647
  CrossrefPubMedGoogle Scholar
• 37 Song C, Horrobin D-F, Leonard B-E. The comparison of changes in behavior, neurochemistry, endocrine, and immune functions after different routes, doses and durations of administrations of IL-1beta in rats.  Pharmacopsychiatry. 2006;  39 ((3)) 88-99
  Article in Thieme ConnectPubMedGoogle Scholar
• 38 Tichomirowa M-A, Keck M-E, Schneider H-J, Paez-Pereda M, Renner U, Holsboer F. et al . Endocrine disturbances in depression.  J Endocrinol Invest. 2005;  28 89-99
  PubMedGoogle Scholar
• 39 Torpy D-J, Grice J-E, Hockings G-I, Crosbie G-V, Walters M-M, Jackson R-V. Effect of sodium valproate on naloxone-stimulated ACTH and cortisol release in humans.  Clin Exp Pharmacol Physiol. 1995;  22 441-443
  CrossrefPubMedGoogle Scholar
• 40 Tunnicliff G, Malatynska E. Central GABAergic systems and depressive illness.  Neurochem Res. 2003;  28 965-976
  CrossrefPubMedGoogle Scholar
• 41 Vielhaber K, Riemann D, Feige B, Kuelz A, Kirschbaum C, Voderholzer U. Impact of experimentally induced serotonin deficiency by tryptophan depletion on saliva cortisol concentrations.  Pharmacopsychiatry. 2005;  38 ((2)) 87-94
  Article in Thieme ConnectPubMedGoogle Scholar
• 42 Wang D, Noda Y, Tsunekawa H, Zhou Y, Miyazaki M, Senzaki K. et al . Behavioural and neurochemical features of olfactory bulbectomized rats resembling depression with comorbid anxiety.  Behav Brain Res. 2007;  178 262-273
  CrossrefPubMedGoogle Scholar
• 43 Williams G-W, McGinnis M-Y, Lumia A-R. The effects of olfactory bulbectomy and chronic psychosocial stress on serum glucocorticoids and sexual behavior in female rats.  Physiol Behav. 1992;  52 755-760
  CrossrefPubMedGoogle Scholar
• 44 Young A-H, Geddes J-R, Macritchie K, Rao S-N, Vasudev A. Tiagabine in the maintenance treatment of bipolar disorders.  Cochrane Database Syst Rev. 2006a;  3 CD005173
  PubMedGoogle Scholar
• 45 Young A-H, Geddes J-R, Macritchie K, Rao S-N, Watson S, Vasudev A. Tiagabine in the treatment of acute affective episodes in bipolar disorder: efficacy and acceptability.  Cochrane Database Syst Rev. 2006b;  3 CD004694
  PubMedGoogle Scholar

Correspondence

Prof. D. Jezova

Institute of Experimental Endocrinology

Slovak Academy of Sciences

Vlarska 3

83306 Bratislava

Slovakia

Phone: +421/2/54 77 38 00

Fax: +421/2/54 77 42 47

Email: ueenjezo@savba.sk